TPG has engaged advisors to explore a sale of Lyric, the healthcare reimbursement software platform it assembled through seven acquisitions since 2020, in a process that could value the business at approximately $5 billion according to sources with knowledge of the matter. The firm acquired the core Lyric assets for an undisclosed sum in late 2020 and has since added complementary revenue cycle management and patient access tools through bolt-ons including $400 million for Equian in 2022.

The timing reflects maturation of TPG's healthcare software thesis rather than distress. Lyric processes an estimated $180 billion in annual healthcare claims across 400 hospital systems and 2,000 physician groups, with recurring revenue concentration in state Medicaid programs and large commercial payers. The platform automates eligibility verification, prior authorization workflows, and claims reconciliation — infrastructure work that hospital CFOs cannot defer even as procedure volumes fluctuate. TPG's Build playbook here followed the Apptio model: acquire a category leader with sticky enterprise contracts, then layer in adjacent workflow tools that increase customer switching costs. Lyric now touches roughly 18% of U.S. hospital revenue cycle touchpoints, a penetration rate that makes competitive displacement expensive for buyers.

The $5 billion ask prices Lyric at roughly 14-16x estimated EBITDA if sources' valuation range holds, a multiple that sits between pure-play revenue cycle management platforms trading at 10-12x and clinical workflow software commanding 18-22x. That compression matters. Healthcare IT multiples peaked in 2021 when Waystar went private at 22x and Athenahealth traded at 18x trailing EBITDA. Today's buyers face 6.5% cost of debt versus 3.2% three years ago, which mechanically lowers what financial sponsors can pay while hitting return thresholds. Strategic acquirers — names like Oracle, Optum, or even CVS — have balance sheet capacity but face antitrust scrutiny on assets touching payer-provider data flows. The Department of Justice blocked Elevance's $3.7 billion attempt to acquire Navinet in 2022 on interoperability grounds, a precedent that shapes diligence timelines here.

TPG's exit window narrows if they want a 2025 close. Most $4-5 billion healthcare IT processes require 120-150 days from first-round bids to signed definitive agreement, plus another 90-120 days for regulatory clearance if a strategic buyer wins. That puts a signing deadline around June if the firm wants to book the exit before their fiscal year-end. Financial sponsor buyers — Blackstone, KKR, and Thoma Bravo have all deployed capital in revenue cycle infrastructure — could move faster but face the same financing cost reality. Watch for signals that TPG is willing to retain a minority stake or provide seller financing, structures that became more common in 2024's larger software processes when bid-ask spreads exceeded 200 basis points.

The Lyric process will clarify whether healthcare reimbursement software still commands scarcity premiums or has repriced as industrial infrastructure. TPG paid an estimated 12-13x for the initial Lyric assets in 2020; exiting at 14-16x after adding $800 million in bolt-on acquisitions delivers a return, but not the 3.5-4.0x cash-on-cash that defined the firm's 2018-2020 software exits. First-round indications are due mid-February according to sources, with management presentations scheduled for March. If bids cluster below $4.5 billion, expect TPG to pull the process and wait for the Fed's next rate decision in June.